Biotech Startups

Open Book Extracts produces GMP and ISO certified CBD isolate products for wellness applications. The company supplies high-purity crystalline CBD powder with USDA organic, kosher, and halal certifications for formulation in dietary supplements and wellness products.

1 investor

Open Stent Solution develops a percutaneous medical device for mitral and tricuspid valve replacement in cardiac patients ineligible for open-heart surgery. The company leverages ribbon-based valve technology to enable less invasive treatment with smaller delivery systems adaptable to various valve sizes.

1 investor

OpenClinica eConsent is a digital consent platform for clinical trials that enables participants to review and electronically sign informed consent forms using media-rich content on any device. It serves academic researchers, sponsors, contract research organizations (CROs), and clinical trial sites who need to streamline enrollment while maintaining regulatory compliance across decentralized, hybrid, and in-person studies.

1 investor

Open Culture builds an automated laboratory platform (Habitat) that autonomously runs cell-culture experiments — perfusing, imaging, and recording living samples — and an AI agent that plans and executes experiments from plain-language descriptions while organizing results into a queryable knowledge graph. It serves neuroscience and biology research labs, drawing on the founders' prior Braingeneers work in electrophysiology and AI.

1 investor

OPKO Health is a fully integrated healthcare company developing multispecific therapies for serious diseases including cancers and infectious diseases, and operates BioReference Laboratories, a clinical reference laboratory serving approximately 11 million patients annually in the U.S.

1 investor

1 investor

A service that recruits customers seeking orthodontic braces through social media and refers them to dental clinics. It operates across multiple prefectures in Japan, serving orthodontic dental clinics.

1 investor

Optic (referred to as Bioptic) applies AI and foundation models to biopharma research and drug discovery, combining machine learning with scientific domain expertise for R&D. The company targets the biopharma industry, aiming to distill scientific knowledge into scalable software for therapeutics development.

1 investor

Optics11 Life develops optical fiber-sensing instruments and software platforms that measure mechanical properties of cells, tissues, and biomaterials to accelerate medical research and drug development. The company partners with life science researchers and laboratories to enable non-destructive characterization of biological samples for applications in drug discovery, tissue engineering, and disease modeling.

1 investor

Opticyte develops the VitalO₂, a preclinical-stage medical device aimed at hospitals, with an FDA De Novo pathway and Breakthrough Device Designation. The company operates in the medical device sector.

1 investor

Optobio makes the Xpress ELISA, a 48-channel automated ELISA instrument with an integrated chemiluminescence detector that delivers results in under an hour using small sample volumes. The device supports multiplexed or single-plexed assays with 18 validated tests for laboratory immunoassay applications.

1 investor

Ora Biomedical is a longevity-science company that developed an AI and robotics platform for high-throughput screening of aging interventions using C. elegans research tools. Spun out of the University of Washington longevity-science community, it works on healthy-aging and regenerative medicine research.

1 investor

Ora-biotics develops a low-dose, sensory-neutral prebiotic fiber ingredient, upcycled from a natural food side stream, designed to be stable in capsules and acidic beverages. The ingredient targets metabolic health outcomes such as weight management and blood glucose control by feeding beneficial gut microbes, and is aimed at product formulators in the food and supplement industry.

1 investor

Orbicle Bio develops carbon-negative organic fertilizers made from naturally-derived microbes and their nutrients to promote crop growth and reduce reliance on synthetic fertilizers. The company targets the agriculture market and expects its first product to be commercially available in 2025/2026.

1 investor

OrbiMed is a global investment firm that manages public equity, private equity, and private credit/royalty strategies focused on the healthcare industry.

1 investor

Orbis Medicines is a drug discovery company developing orally bioavailable macrocycle drug candidates as alternatives to injectable biologics, targeting both intracellular and extracellular protein targets. It uses a proprietary chemistry and machine-learning platform to systematically explore macrocycle chemical space and generate optimized drug candidates.

1 investor

1 investor

Orchidia is a pharmaceutical company that completed a third investment round in 2026 with strategic international investors including SPE Capital, Proparco, EBRD, and BIO.

1 investor

Orenitram is a prescription oral medication containing treprostinil, indicated to treat pulmonary arterial hypertension (PAH) by slowing disease progression and improving exercise capacity in adults. The site is a drug information page covering safety, dosing, and side-effect details for patients and healthcare providers.

1 investor

Organ Recovery Systems develops organ preservation products and services, including machine perfusion technology for donor kidneys, for transplant programs and transplant professionals. The company supports over 400 transplant programs across 49 countries and also provides clinical and technical support services.

1 investor

Organo-ID develops iPSC-derived organoid systems, including 3D hepatocyte models, to test drugs in better-modeled biological systems for predictive diagnostics and personalized therapies. The company serves drug development and treatment applications in oncology and rare disease, operating from Turkey with a global focus.

1 investor

Organogenesis is a regenerative medicine company that develops and commercializes products for the advanced wound care and surgical biologics markets, supplying clinicians and their patients. Its product portfolio includes tissue-based therapies such as Apligraf for wound care.

1 investor

Orgenesis provides decentralized manufacturing infrastructure for cell and gene therapies, enabling on-site processing of CGTs in regional centers through its POCare™ platform and OMPUL™ mobile processing units. The company aims to reduce costs, shorten development timelines, and improve patient access to personalized cell and gene therapies.

1 investor

ORIA is a Paris-based company, spun off from ENS Paris in 2022, that uses a proprietary mechanical microfluidic platform to extract intact, high-purity functional organelles at industrial scale. Its organelle products serve pharmaceutical companies, biotech firms, and academic institutions for drug discovery, disease modeling, and therapeutic research.

1 investor